Hasten Biopharmaceutic Co., Ltd (China) ("Hasten") today announced that it has acquired the commercial rights in China for Rocephin^®, a long-acting, broad spectrum cephalosporin antibiotic, from Swiss multinational healthcare company, Roche. Following the closing of the transaction earlier this year, there will be a transition period between Hasten and Roche.

Under the agreement, Hasten acquired Roche's China mainland rights for Rocephin^®, including the product's marketing authorization and certain intellectual property, including trademarks. As a critical care product, Rocephin^® is a broad-spectrum antibiotic with strong brand value.

"Hasten is committed to building a leading innovative medical and healthcare enterprise in China. The acquisition of Rocephin^® delivers strong commercial synergy with Hasten's current critical care portfolio in the Emergency Room, Intensive Care Unit, and Surgery departments, and positions us well to continue providing best-in-class treatments to benefit more patients," Summer Xia, CEO of Hasten Biopharma, said.

Hasten is an investment of CBC Group, Asia's largest healthcare-dedicated investment firm headquartered in Singapore, Hefei Industry Investment Group, and Feidong County of Hefei City.